Subscribe!
Six Peptides, One Major Policy Shift: What RFK Jr.’s Decision Really Means – Kevin Kearns
By Coach Kevin Kearns | Founder, Burn With Kearns & BWK Authentic Edge
The future of peptide access, regenerative medicine, and the importance of asking better questions.
For more than 30 years, I’ve worked in health, fitness, and human performance. I’ve watched trends come and go. I’ve seen exciting innovations change the conversation, and I’ve seen promising ideas promoted long before the science caught up.
That’s why a recent development in Washington deserves our attention.
On October 30, 2026, the U.S. Department of Health and Human Services announced an interim policy involving six peptides that have generated significant interest in longevity and regenerative medicine.
The policy, issued under HHS Secretary Robert F. Kennedy Jr., provides limited enforcement discretion for certain licensed pharmacies and physicians compounding these peptides under specific conditions.
It’s a meaningful development. But let’s get something straight from the beginning:
This is not FDA approval. It is not proof of safety or effectiveness. And it is not a free pass for anyone to manufacture or sell these substances.
What it represents is a shift in how federal health officials are approaching access to a group of compounds that have attracted considerable scientific and public interest.
Meet the Six Peptides
- BPC-157 — The Recovery Conversation
BPC-157 is a synthetic peptide sequence derived from a protein associated with gastric juice.
It’s attracted attention for its potential role in tissue repair, tendon and ligament research, and gastrointestinal protection.
Much of that interest comes from laboratory and animal studies.
The important distinction? Promising preclinical findings do not establish effectiveness or safety in humans.
- TB-500 — Tissue Repair and Regeneration
TB-500 is a peptide fragment associated with thymosin beta-4 research.
Researchers have investigated biological pathways involving cell migration, inflammation, and tissue repair.
It’s frequently discussed in athletic recovery circles.
However, its clinical benefits and safety profile in humans remain inadequately established.
- KPV — Inflammation and Gut Health
KPV is a three-amino-acid peptide studied for its potential anti-inflammatory properties.
Researchers have explored its activity in experimental models involving intestinal and skin inflammation.
It’s an interesting area of investigation, particularly as we learn more about inflammatory pathways.
But clinical evidence in humans remains limited.
- MOTS-c — Metabolism and Mitochondrial Research
MOTS-c has generated interest because of its relationship to mitochondrial biology and metabolic signaling.
Scientists are studying how mitochondrial-derived peptides may influence energy regulation and cellular responses to metabolic stress.
Could this research eventually contribute to our understanding of metabolic health and aging?
Possibly.
But the therapeutic potential of MOTS-c in humans is not yet established.
- Epitalon — Aging and Cellular Biology
Epitalon is a synthetic tetrapeptide investigated in aging-related research.
Its proposed effects on cellular aging and telomerase activity have attracted considerable attention.
These hypotheses deserve careful investigation.
They should not, however, be confused with demonstrated human longevity benefits.
- Semax — Brain Health and Neurological Research
Semax is a synthetic peptide studied for potential neurological effects, including cognition and responses to neurological injury.
It has a history of research and use in certain countries outside the United States.
But evidence from other regulatory jurisdictions does not establish FDA approval or demonstrated effectiveness for US patients.
Six peptides. Six different research conversations. One common responsibility: follow the evidence.
What Did HHS Actually Change?
The new policy concerns Section 503A of the Federal Food, Drug, and Cosmetic Act.
Under specified conditions, HHS says it does not intend to pursue enforcement against qualifying state-licensed pharmacies, federal facilities, and licensed physicians that compound products using these six substances.
Those conditions include requirements relating to ingredient sourcing, documentation, specific dosage forms and routes of administration, patient-specific prescriptions, labeling, and adverse-event reporting.
The peptides have not been added to the FDA’s official 503A Bulks List.
And this policy does not automatically apply to 503B outsourcing facilities or authorize unrestricted commercial distribution.
This distinction matters tremendously.
Access is not approval. Compounding is not the same as FDA-reviewed manufacturing. And availability does not establish clinical benefit.
Why Quality and Transparency Matter More Than Ever
One of the most important conversations surrounding peptides isn’t just what a molecule might do.
It’s where the substance comes from and how its identity, purity, quality, and consistency are established.
As consumers and medical professionals explore this field, I believe we need to ask better questions.
Who manufactures the active ingredient?
What analytical testing supports its identity and purity?
What documentation is available?
How are storage, transportation, and traceability handled?
And most importantly, what does the human clinical evidence actually demonstrate?
A certificate of analysis is useful, but it doesn’t replace clinical safety and effectiveness data.
Nor does a claim of manufacturing quality automatically establish regulatory authorization.
Knowing your source means understanding both the product and the evidence behind it.
My Perspective After Three Decades in Human Performance
I’ve spent much of my career challenging conventional thinking about exercise, recovery, and performance.
And I’m still a student.
That’s particularly important in regenerative medicine.
I believe innovation should be explored. I believe researchers should be encouraged to ask difficult questions. And I believe patients deserve accurate information about emerging technologies.
But scientific curiosity must be accompanied by scientific discipline.
As my colleague Kennedy Lodato recently emphasized in our educational series:
Mechanism is not outcome.
Understanding what a molecule does in a laboratory is not the same as demonstrating meaningful results in a well-designed human clinical trial.
That’s not a reason to abandon innovation.
It’s a reason to investigate it properly.
What Comes Next?
The HHS policy is interim. Further regulatory review, public input, and rulemaking may change the landscape.
For physicians, pharmacists, researchers, and organizations working in this field, the next chapter should involve better characterization, stronger clinical research, transparent documentation, and responsible oversight.
For consumers, the message is equally important:
Ask questions. Understand the evidence. Work with qualified healthcare professionals. Never confuse enthusiasm with proof.
At BWK Authentic Edge, we’re committed to keeping education at the center of the conversation as we explore developments in peptides, regenerative medicine, and longevity.
Because the future of health innovation shouldn’t be built on hype.
It should be built on knowledge, accountability, and evidence.
Innovation deserves investigation. Evidence earns confidence.
Protect what you have. Pursue what’s possible.
Find your edge.
— Coach Kevin Kearns
Founder, Burn With Kearns & BWK Authentic Edge
www.BWKAuthenticEdge.com
Educational information only. This article is not medical advice or an endorsement of using unapproved peptides. Compounded drugs are not FDA-approved, and the safety and effectiveness of these six peptides for the discussed uses have not been established through FDA approval.
Sources: US Department of Health and Human Services, Interim Enforcement Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (October 2026); FDA, Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks; Federal Food, Drug, and Cosmetic Act, Section 503A.